Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.04. | XOMA Corporation: XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% | 1 | GlobeNewswire (USA) | ||
25.04. | XOMA Corp - 8-K, Current Report | 1 | SEC Filings | ||
25.04. | XOMA Corporation: XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) | 47 | GlobeNewswire (Europe) | XOMA is entitled to a mid-single digit royalty on global OJEMDA sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement... ► Artikel lesen | |
03.04. | XOMA Corp - 8-K, Current Report | - | SEC Filings | ||
03.04. | XOMA Corporation Announces Closing of Tender Offer | 105 | GlobeNewswire (Europe) | EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies... ► Artikel lesen | |
02.04. | Dividendenbekanntmachungen (02.04.2024) | 5.836 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BANCO BRADESCO SA BRBBDCACNPR8 0,0189 BRL 0,0035 EUR BANCO BRADESCO SA ADR US0594604029 0,0034 USD 0,0032 EUR BANCO BRADESCO SA... ► Artikel lesen | |
21.03. | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 2 | Seeking Alpha | ||
21.03. | XOMA Preferred Shares Series A declares $0.5391 dividend | 1 | Seeking Alpha | ||
19.03. | XOMA Corporation: XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. | 57 | GlobeNewswire (Europe) | EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation ("XOMA" or the "Company"; Nasdaq: XOMA) entered into a merger agreement to acquire... ► Artikel lesen | |
11.03. | XOMA Corp - S-4, Registration of securities, business combinations | 4 | SEC Filings | ||
08.03. | XOMA Corporation files $200M mixed securities shelf | 6 | Seeking Alpha | ||
08.03. | XOMA Corp reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
08.03. | XOMA Corp - 10-K, Annual Report | 2 | SEC Filings | ||
08.03. | Recap: XOMA Q4 Earnings | 1 | Benzinga.com | ||
08.03. | XOMA GAAP EPS of -$4.04 misses by $1.99, revenue of $4.76M misses by $1.74M | 1 | Seeking Alpha | ||
08.03. | XOMA Corp - 8-K, Current Report | 1 | SEC Filings | ||
08.03. | XOMA Corporation: XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value | 78 | GlobeNewswire (Europe) | Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related... ► Artikel lesen | |
28.02. | XOMA Corporation: XOMA to Present at Upcoming Investor Conferences in March | 2 | GlobeNewswire (USA) | ||
16.02. | Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma | 3 | Benzinga.com | ||
16.02. | Kinnate Hikes on Merger with XOMA | 2 | Baystreet.ca |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 9,540 | -0,68 % | EQS-News: Evotec SE: Bayer und Evotec vereinbaren Forschungskollaboration in der Präzisionskardiologie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Bayer und Evotec vereinbaren Forschungskollaboration in der Präzisionskardiologie
30.04.2024 / 08:30 CET/CEST
Für den... ► Artikel lesen | |
QIAGEN | 39,820 | +0,49 % | Qiagen schwächelt - Aktie rutscht ab | Im ersten Quartal 2024 verzeichnete der Labordienstleister und Diagnostikspezialist Qiagen schwächelnde Ergebnisse. Die andauernde Nachfrageflaute drückte auf Umsatz und Ergebnis. Das belastet die Aktie... ► Artikel lesen | |
CG ONCOLOGY | 33,950 | -3,28 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
KEROS THERAPEUTICS | 58,68 | 0,00 % | Keros Therapeutics files automatic mixed shelf | ||
VERA THERAPEUTICS | 44,970 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
BIONTECH | 85,20 | -0,23 % | Evotec, Vidac Pharma, BioNTech - das Milliardenrennen um die Krebstherapie | Die Onkologie steht an der Schwelle zu einer goldenen Ära. Getrieben von einer Zunahme der Krebserkrankungen und beeindruckenden wissenschaftlichen Fortschritten, darunter Gen- und Immuntherapien, eröffnet... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 5,310 | 0,00 % | Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 21,230 | +4,43 % | Edgewise Therapeutics, Inc. - 8-K, Current Report | ||
MORPHOSYS | 66,80 | -0,15 % | Morphosys: Barclays stockt auf - Aktie im Aufwind | Die Aktie von Morphosys hat sich am Dienstag von ihren jüngsten Verlusten erholt, was auf eine Mischung von Marktanalysen und spekulativen Entwicklungen zurückzuführen ist. Insbesondere die Neubewertung... ► Artikel lesen | |
DYNE THERAPEUTICS | 25,650 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
KYMERA THERAPEUTICS | 38,440 | +0,34 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 17,080 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate Progress | OJEMDA (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,795 | 0,00 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
ARCELLX | 52,42 | 0,00 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
JANUX THERAPEUTICS | 61,47 | 0,00 % | Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen |